A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Hale, Laura P ^a   Greer, Paula K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 9; METRONIDAZOLE; OMEPRAZOLE; PIROXICAM; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CANCER RISK; CLINICAL FEATURE; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; ENTERITIS; FEMALE; HISTOPATHOLOGY; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERMEABILITY BARRIER; PROTEIN DEFICIENCY; TH17 CELL; ULCERATIVE COLITIS; WEANING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREEDING; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ENTEROBACTERIACEAE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); MURINAE; MUS;

EID: 84864414700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041797     Document Type: Article

References (36)

1. Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, et al.((2009)) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. New Engl J Med. 361:: 2033--2045.
2. Van der Linde K, Boor PPC, Sandkuijl LA, Meijssen MAC, Savelkoul HFJ, et al.((2003)) A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in Crohn disease. Scand J Gastroenterol 38:: 611--617.
3. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, et al.((2008)) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nature Genet. 40:: 1319--1323.
4. Mottet C, Uhlig HH, Powrie F,((2003)) Cutting edge: Cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 170:: 3939--3943.
5. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, et al.((2009)) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunol. 10:: 1178--1184.
6. Wilke CM, Wang L, Wei S, Kryczek I, Huang E, et al.((2011)) Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Translat Med. 9:: 217.
7. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W,((1993)) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:: 263--274.
8. Chichlowski M, Sharp JM, Vanderford DA, Myles MH, Hale LP,((2008)) Helicobacter typhlonius and H. rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL-10-deficient mice. Comp Med. 58:: 534--541.
9. Chichlowski M, Westwood GS, Abraham SN, Hale LP,((2010)) Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia. PLOS One 5:: e12220.
10. Hale LP, Perrera D, Gottfried MR, Maggio-Price L, Srinivasan S, et al.((2007)) Neonatal infection with Helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10-/- mice. Helicobacter. 12:: 598--604.
11. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, et al.((2002)) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterol. 123:: 1527--1542.
12. Hale LP, Gottfried MR, Swidsinski A,((2005)) Piroxicam treatment of IL-10 deficient mice enhances colon epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm. Bowel Dis. 11:: 1060--1069.
13. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, et al.((1999)) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 340:: 1398--1405.
14. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH,((2003)) Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacol. 37:: 1256--1265.
15. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al.((2002)) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:: 1541--1549.
16. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, et al.((2004)) Infliximab maintenance therapy for fistulizing Crohn's disease. New Engl J Med. 350:: 876--885.
17. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al.((2005)) Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl J Med. 353:: 2462--2476.
18. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, et al.((2001)) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterol. 121:: 1088--1094.
19. Hale LP, Cianciolo G,((2008)) Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. J. Inflamm. 5:: 4.
20. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, et al.((2001)) Helicobacter-induced inflammatory bowel disease in IL-10 and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol. 281:: G764--G778.
21. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, et al.((2003)) Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterol. 124:: 762--777.
22. Ekbom A, Helmick C, Zack M, Adami HO,((1990)) Ulcerative colitis and colorectal cancer. A population-based study. New Engl J Med. 323:: 1228--1233.
23. Nordenholtz KE, Stowe SP, Stormont JM, Stowe MM, Chessin LN, et al.((1995)) The cause of death in inflammatory bowel disease: a comparison of death certificates and hospital charts in Rochester, New York. Am J Gastroenterol. 90:: 927--932.
24. Eaden JA, Abrams KR, Mayberry JF,((2001)) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:: 526--535.
25. Munkholm P,((2003)) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18:: 1--5.
26. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, et al.((1996)) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ Th1-like responses. J Clin Invest. 98:: 1010--1020.
27. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, et al.((2001)) Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22:: 665--671.
28. Hill DA, Artis D,((2010)) Intestinal bacteria and regulation of immune cell homeostasis. Ann Rev Immunol. 28:: 623--667.
29. Chichlowski M, Hale LP,((2008)) Bacterial-mucosal interactions in inflammatory bowel disease - an alliance gone bad. Amer. J. Physiol. 295:: G1139--G1149.
30. Mahadevan U,((2009)) Pregnancy and inflammatory bowel disease. Gastroenterol Clin N Am. 38:: 629--649.
31. UK IBD Genetics Consortium & the Wellcome Trust Case Control Consortium,((2009)) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nature Genet. 41:: 1330--1334.
32. Ericsson AC, Myles M, Davis W, Ma L, Lewis M, et al.((2010)) Noninvasive detection of inflammation-associated colon cancer in a mouse model. Neoplasia 12:: 1054--1065.
33. Tang C, Chen S, Qian H, Huang W,((2011)) Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunol 135:: 112--124.
34. Malaviya R, Ikeda T, Ross E, Abraham SN,((1996)) Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381:: 77--80.
35. Echtenacher B, Mannel DN, Hultner L,((1996)) Critical protective role of mast cells in a model of acute septic peritonitis. Nature 103:: 75--77.
36. Stallmach A, Hagel S, Bruns T,((2010)) Adverse effects of biologics used for treating IBD. Best Pract & Res Clin Gastroenterol. 24:: 167--182.